Golimumab clinical trials
Also written Simponi and CNTO 148.
How each study uses golimumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the golimumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 24 Apr 2009 · SIMPONI · BLA 125289 (FDA, Drugs@FDA)
- European Union
- 1 Oct 2009 · Simponi · EMEA/H/C/000992 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
72 studies that test it; most in 2013 (7)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 5 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 5 |
| 2011 | 1 |
| 2012 | 5 |
| 2013 | 7 |
| 2014 | 6 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 44 · Other 28
Janssen Research & Development, LLC (15) · Centocor, Inc. (15) · Merck Sharp & Dohme LLC (6) · Janssen Pharmaceutical K.K. (2) · Janssen Biotech, Inc. (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Shanghai Mental Health Center (2) · The Leeds Teaching Hospitals NHS Trust (1)
Often tested with
Tested in the same studies.
Infliximab (8) · Methotrexate (7) · Etanercept (6) · Adalimumab (6) · Abatacept (4) · Certolizumab Pegol (4) · Guselkumab (3) · Ustekinumab (3)
Related medicines
As reviewed, each with the page that says it.
- One of Immunosuppressive Agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Golimumab is the comparator. A study of two new drugs counts under both.
- 1Guselkumab · University of Pennsylvania
Studies
Open first, then newest update. How each study uses golimumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 72
- Withdrawal Versus Continued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile Idiopathic ArthritisNot yet recruitingPhase 4Oslo University HospitalNCT07904780Written as GolimumabHow we know
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as GolimumabHow we know
- Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs PlaceboNot yet recruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT07683026Written as GolimumabHow we know
- Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseRecruitingPhase 3University of NebraskaNCT03414502Written as GolimumabHow we know
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic ArthritisRecruitingPhase 3University of Erlangen-Nürnberg Medical SchoolNCT04610476Written as GolimumabHow we know
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingPhase 2Janssen Research & Development, LLCNCT05242484Written as GolimumabHow we know
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's DiseaseActive, not recruitingPhase 2Janssen Research & Development, LLCNCT05242471Written as GolimumabHow we know
- Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP StudyTerminatedPhase 2University of WashingtonNCT05960578Written as GolimumabHow we know
- A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingPhase 3Janssen Research & Development, LLCNCT03596645Written as GolimumabHow we know
- A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic ArthritisCompletedPhase 2Janssen Research & Development, LLCNCT05071664Written as GolimumabHow we know
- GOLimumab and Methotrexate Versus Methotrexate in Very Early PsACompletedPhase 3The Leeds Teaching Hospitals NHS TrustNCT04108468Written as GolimumabHow we know
- A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate TherapyCompletedPhase 3Janssen Research & Development, LLCNCT02277444Written as GolimumabHow we know
- A Study of Golimumab in Participants With Active Ankylosing SpondylitisCompletedPhase 3Janssen Research & Development, LLCNCT02186873Written as GolimumabHow we know
- Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut InflammationCompletedPhase 3University GhentNCT03270501Written as GolimumabHow we know
- A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic ArthritisCompletedPhase 4Johnson & Johnson Private LimitedNCT03733925Written as GolimumabHow we know
- A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)CompletedPhase 4Janssen Scientific Affairs, LLCNCT01804166Written as GolimumabHow we know
- A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 DiabetesCompletedPhase 2Janssen Research & Development, LLCNCT02846545Written as GolimumabHow we know
- A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 DiabetesCompletedPhase 1Janssen Research & Development, LLCNCT03298542Written as GolimumabHow we know
- Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy SubjectsCompletedPhase 1Bio-Thera SolutionsNCT04152759Written as Drug: BAT2506 injection Other Names: Simponi(EU-licensed)How we know
- Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)CompletedPhase 4Merck Sharp & Dohme LLCNCT03253796Written as GolimumabHow we know
See all 72 studies that test golimumab →
Given beside what is tested · 5 — golimumab is usual care or a partner of the new treatment
- A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial SpondyloarthritisTerminatedPhase 3Janssen Research & Development, LLCNCT02437162Written as Golimumab 50 mgHow we know
- A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial SpondyloarthritisTerminatedPhase 3Janssen Research & Development, LLCNCT02438787Written as Golimumab 50 mgHow we know
- Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEXCompletedPhase 3Alvotech Swiss AGNCT05842213Written as Simponi (Golimumab)How we know
- NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing SpondylitisCompletedPhase 4Charite University, Berlin, GermanyNCT02758782Written as GolimumabHow we know
- A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate TherapyCompletedPhase 3Janssen Pharmaceutical K.K.NCT00727987Written as CNTO 148How we know
As the comparator · 6 — what is tested is compared with golimumab
- Guselkumab vs Golimumab in PsA TNF Inadequate Responder PatientsActive, not recruitingPhase 3University of PennsylvaniaNCT05669833Written as GolimumabHow we know
- A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult ParticipantsCompletedPhase 1Alvotech Swiss AGNCT05632211Written as SimponiHow we know
- A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®CompletedPhase 1Bio-Thera SolutionsNCT05332730Written as Simponi® (EU commercially available product)How we know
- Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGETCompletedPhase 4Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesNCT02425865Written as GOLIMUMABHow we know
- Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGationTerminatedPhase 4Mario Negri Institute for Pharmacological ResearchNCT03100253Written as GolimumabHow we know
- Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α BlockersTerminatedPhase 2SanofiNCT01217814Written as GolimumabHow we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Newly registered1
Codes
What other systems call golimumab · ClinicalTrials.gg INT005277
- MeSH (NLM) C529000golimumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 91X1KLU43EGOLIMUMABConfirmed FDA, NLM, Wikidata
- RxNorm 819300Confirmed FDA, Wikidata
- Wikidata Q413879golimumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C87766GolimumabOne source FDA
- DrugBank DB06674One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C529000 | golimumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 91X1KLU43E | GOLIMUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 819300 | — | Confirmed FDA, Wikidata |
| Wikidata | Q413879 | golimumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C87766 | Golimumab | One source FDA |
| DrugBank | DB06674 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.